替罗非班治疗超溶栓时间窗急性脑梗死的临床研究  

Clinical Study of Tirofiban in the Treatment of Acute Cerebral Infarction with Hyperthrombolytic Time Window

作　　者：付娜娜 王通 解晗 FU Nana;WANG Tong;XIE Han(Department of Neurology,Juye County People's Hospital,Heze 274900,Shandong,China)

机构地区：[1]巨野县人民医院神经内科,山东菏泽274900

出　　处：《系统医学》2025年第4期110-113,共4页Systems Medicine

摘　　要：目的探讨超静脉溶栓时间窗(6~24 h)患者早期应用替罗非班治疗急性脑梗死的效果。方法回顾性选取巨野县人民医院于2022年1月—2024年1月收治的82例超溶栓时间窗脑梗死患者的临床资料。根据治疗方法不同分组,参照组(n=41)采用阿司匹林药物+硫酸氢氯吡格雷药物展开双抗治疗;研究组(n=41)采用静脉予替罗非班后桥接双抗治疗。比较两组神经功能、疗效、不良反应发生情况。结果与参照组治疗90 d时的神经功能比较,研究组更优,差异有统计学意义(均P<0.05)。与对照组的68.29%(28/41)相比,研究组90 d时的治疗总有效率87.80%(36/41)更高,差异有统计学意义(χ^(2)=4.555,P<0.05)。两组不良反应(血小板减少、消化道出血、颅内出血、牙龈出血、皮肤黏膜出血)发生情况比较,差异无统计学意义(P>0.05)。结论对超溶栓时间窗急性脑梗死患者,早期静脉使用替罗非班效果明显,安全性较好。Objective To investigate the efficacy and safety of early application of tirofiban in the treatment of acute cerebral infarction with super-venous hyperthrombolytic time window(6-24 h).Methods The clinical data of eighty-two patients with cerebral infarction beyond thrombolysis time window admitted to Juye County People's Hospital from January 2022 to January 2024 were retrospectively selected.According to the different treatment methods,the reference group(n=41)was treated with aspirin+clopidogrel bisulfate.The study group(n=41)was treated with intravenous tirofiban followed by bridging dual antiplatelet therapy.Compare the neurological function,total effective rate of treatment and adverse reactions.Results The comparison of neurological function between the two groups after 90 days of treatment showed that the study group was superior to the reference group,and the differences were statistically significant(both P<0.05).Compared with the control group's 68.29%(28/41),the total effective rate of treatment in the study group at 90 days of 87.80%(36/41)was higher,and the difference was statistically significant(χ^(2)=4.555,P<0.05).The overall incidence of adverse effects(thrombocytopenia,gastrointestinal bleeding,intracranial bleeding,gingival bleeding,skin and mucosal bleeding)between the study group and the control group was compared,the difference was not statistically significant(P>0.05).Conclusion For patients with acute cerebral infarction with super hyperthrombolytic time window,early intravenous use of tirofiban is effective and safe.

关 键 词：替罗非班 超溶栓时间窗 急性脑梗死 疗效 安全性 

分 类 号：R743[医药卫生—神经病学与精神病学]